Study your flashcards anywhere!

Download the official Cram app for free >

  • Shuffle
    Toggle On
    Toggle Off
  • Alphabetize
    Toggle On
    Toggle Off
  • Front First
    Toggle On
    Toggle Off
  • Both Sides
    Toggle On
    Toggle Off
  • Read
    Toggle On
    Toggle Off
Reading...
Front

How to study your flashcards.

Right/Left arrow keys: Navigate between flashcards.right arrow keyleft arrow key

Up/Down arrow keys: Flip the card between the front and back.down keyup key

H key: Show hint (3rd side).h key

A key: Read text to speech.a key

image

Play button

image

Play button

image

Progress

1/10

Click to flip

10 Cards in this Set

  • Front
  • Back
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) includes:
a.
b.
c.
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) includes:
a. Nevirapine (Viramune)
b. Delavirdine (Rescriptor)
c. Efavirenz (Sustiva)
Nevirapine (Viramune)
method of action:
Nevirapine (Viramune)
method of action: interfere with the viral life cycle by binding to the reverse transcriptase enzyme and thereby PREVENTING CONVERSION OF RNA TO DNA
* no nucleoside analog
Nevirapine (Viramune)
pharmacotherapy:
Nevirapine (Viramune)
pharmacotherapy:
a. Combination therapy for management of HIV infection
b. Prevention of maternal transmission
Nevirapine (Viramune)
safety profile:
Nevirapine (Viramune)
safety profile:
a. Rash
1. Common, appears within first 6 weeks of therapy
2. Usually mild-moderate but can be life-threatening (STEVENS JOHNSON SYNDROME)
3. Initiate therapy with half-dose for first 2 weeks to reduce rash frequency

b. Fever
c. Nausea
d. Elevated liver function tests
e. Drug interactions- Induces hepatic enzyme CYP3A; may reduce serum levels of protease inhibitor antiretrovirals, oral contraceptives, methadone and other drugs metabolized by this system
Delavirdine (Rescriptor)
method of action:
Delavirdine (Rescriptor)
method of action: non-nucleoside reverse transcriptase inhibitor
Delavirdine (Rescriptor)
pharmacotherapy:
Delavirdine (Rescriptor)
pharmacotherapy: Combination therapy for management of HIV infection
Delavirdine (Rescriptor)
safety profile:
Delavirdine (Rescriptor)
safety profile:
a. Rash (up to 18% incidence)
b. GI intolerance (n/v/d); increased liver enzymes
c. Drug interactions- delavirdine INHIBITS liver metabolizing enzymes
Efavirenz (Sustiva)
method of action:
Efavirenz (Sustiva)
method of action: non-nucleoside reverse transcriptase inhibitor
Efavirenz (Sustiva)
pharmacotherapy:
Efavirenz (Sustiva)
pharmacotherapy: Combination therapy for management of HIV infection
Efavirenz (Sustiva)
safety profile:
Efavirenz (Sustiva)
safety profile:
a. CNS symptoms
*warn patients not to perform hazardous duties
b. Skin Rash: 27% incidence, may be severe in rare patients
c. Increased liver enzymes
d. Drug interactions- efavirenz INDUCES liver metabolizing enzyme CYP3A4